What You Should Know: - Nectin Therapeutics Ltd., (Nectin) a biotechnology company developing novel targeted immunotherapies to address resistance to approved immune-oncology treatments, announced it has extended its Series A financing to over $25 million. IBF and Peregrine Ventures led the round, with participation from aMoon Fund and other existing investors. - The funding will be used to support the ongoing clinical evaluation of NTX1088, and to further advance the company’s pipeline of
Read More
MD Anderson Taps Syntrophy to Aggregate Disparate Data, Enable Team Science
What You Should Know: - The University of Texas MD Anderson Cancer Center announced efforts to advance its capabilities to seamlessly connect basic science, translational and clinical research data for the benefit of patients through a technology collaboration with Syntropy and the Foundry platform. - This initiative is part of MD Anderson’s new Strategy aimed at focusing its mission to end cancer on approaches that maximize the impact on humanity, which
Read More
Mission Bio Lands $70M to Expand Cancer Therapies With Single-Cell Multi-Omics Platform
What You Should Know: - Mission Bio raises $70 million in Series C funding led by
Novo Growth to accelerate the development of cancer therapies with single-cell multi-omics. - Mission Bio’s Tapestri Platform, the first single-cell platform capable of detecting DNA and protein changes simultaneously, gives a profound insight into the mutations that drive disease to accelerate the development of novel treatments and save patient lives. Mission Bio,
Inc., a South San Francisco,
Read More
MD Anderson, Philips Partner on Personalized Oncology Treatments, Clinical Trial Matching
What You Should Know: - Philips and MD Anderson collaborate to facilitate
personalized oncology treatments and clinical trial matching based on genomic
markers. - Philips connects oncologists and pathologists around
the world to MD Anderson’s Precision Oncology Decision Support (PODS) system of
actionable clinical information Philips and The University of Texas MD Anderson Cancer
Center today announced a collaboration to provide oncologists with
evidence-based therapy and clinical
Read More
Notable Nabs $40M to Expand Drug Discovery Platform for Personalized Oncology
Notable, a San Francisco, CA-based company redefining cancer treatment with a clinically validated platform that rapidly advances cancer drug development has raised $40M in Series B funding. The Series B round is co-led by B Capital Group and LifeForce Capital. LifeForce is a returning investor, joined by new investors B Capital and Industry Ventures. This latest round brings Notable’s total funding to over $55M.Notable was founded in 2017 by Matt De Silva after helping his own father Marc, who
Read More
Vida Health Raises $30M for Personalized Virtual Care Platform for Physical & Behavioral Health
Vida Health, a personalized virtual care platform for physical and behavioral health has raised $30M in Series C funding from strategic investors including GuideWell Mutual Holding Corporation, Teladoc Health, and Workday Ventures. Existing investors from previous rounds also participated.Impact of Chronic Disease in the U.S.Sixty percent of adults in the United States have one chronic disease, and 40% have two or more. More than 68% of adults with a mental health condition have at least one
Read More
MD Anderson Kicks Off Apple Watch Pilot for Breast Cancer Patients
Back in May, MD Anderson Cancer Center at Cooper announced it was teaming up with behavioral health technology company Polaris Health Directions (Polaris) on an behavioral health pilot project using the Apple Watch to help improve breast cancer treatment outcomes. This week, the pilot project officially kicked off reaching patient hands (wrists) for the first time via the Apple Watch. The partnership brings together MD Anderson Cooper’s expertise in oncology and Polaris’s deep experience in
Read More
